Corrections

The article ‘Crystal arthritis – managing gout and calcium pyrophosphate deposition disease’ by Dr Patrick Baquir, Dr Jang Yoon and Dr Ken Cai, which was published in the April 2024 issue of Medicine Today (pages 23-32), contains an error. The maximum daily dose of febuxostat approved in Australia was erroneously stated as 120mg. This is incorrect; the maximum daily dose of febuxostat approved in Australia is 80mg daily. This has been corrected on page 28 and in Table 1. We apologise for this oversight and any confusion it may have caused. The online version and full-text PDF of this article are correct at https://medicinetoday.com.au/mt/2024/april/feature-article/crystal-arthritis-managing-gout-and-calcium-pyrophosphate-deposition-disease.

The article ‘IgE-mediated food allergies in infants and children: an update on prevention and management’ by Dr Eric Lee and Dr Preeti Joshi, which was published in the March 2024 issue of Medicine Today (pages 12 to 21), contains errors. In the section on ‘Supportive management of anaphylaxis and adrenaline autoinjector prescribing’ on page 18, the text states that ‘brand substitution is not permitted on prescribing, as the device mechanisms differ’. This is incorrect, as brand substitution is allowed for the 150 mcg and 300 mcg devices. In Figure 2b, an image of the Anapen device was incorrectly labelled with the dose of 300 microgram. This is incorrect, and the dose should be 500 microgram. We apologise for these errors and any confusion they may have caused. The online version and full-text PDF of this article are correct at https://medicinetoday.com.au/mt/2024/march/feature-article/ige-mediated-food-allergies-infants-and- children-update-prevention-and-management.